2019.11.01
医療従事者向け がん治療情報解説サイト「 OncoTribune （オンコトリビューン）」に、当院下部消化器外科副部長 賀川義規 医師の2019年欧州臨床腫瘍学会学術集会（ESMO Congress 2019）レポートが掲載されました。
ESMO Congress 2019 FLASH REPORT – 526PD –
TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
https://www.oncotribune.com/report/esmo-co2019/526pd.html
ESMO Congress 2019 FLASH REPORT – 525O –
ACHIEVE-2 trial: a randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)
https://www.oncotribune.com/report/esmo-co2019/525o.html
ESMO Congress 2019 FLASH REPORT – LBA30_PR –
Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration (ID 5478)
印刷用のページを表示
